Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Serum hepcidin a biomarker for restless leg syndrome

30 Jul 2020

Regardless of treatment, serum hepcidin is elevated in patients with restless leg syndrome (RLS) and may act as a biomarker for this condition, a recent study has found.

The study included 102 drug-free RLS patients (median age, 58.9 years; 63 women) whose serum levels of hepcidin and ferritin were measured using the appropriate immunoassays. Participants also underwent a one-night polysomnography in the sleep laboratory. A parallel group of 73 controls (median age, 56.8 years; 45 women) was also included.

Hepcidin levels were significantly elevated in RLS patients even after controlling for body mass index (median, 18.36 vs 11.89 µg/L; p<0.01). Categorizing patients into tertiles of hepcidin showed that that number of patients in each category grew with increasing hepcidin concentration. No such trend was observed for controls.

Receiver operating characteristic curve analysis found that at a hepcidin cut-off of 18.1 µg/L, serum concentrations became a decent discriminator of RLS, with a sensitivity of 52 percent and a specificity of 75 percent.

In contrast, ferritin was slightly higher in RLS patients than in controls upon unadjusted analysis, and this interaction was attenuated after controlling for body mass index.

“Due to the easy-to-use [enzyme-linked immunosorbent assay], hepcidin quantification could be implemented in the routine clinical practice, in view of a possible personalized approach before therapeutic management and potentially with hepcidin antagonists in some patients with RLS,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.